NYSEARCA:LCTX
Lineage Cell Therapeutics, Inc. Stock News
$1.03
-0.0200 (-1.90%)
At Close: May 23, 2024
Lineage Cell Therapeutics, Inc. (LCTX) CEO Brian Culley on Q2 2022 Results - Earnings Call Transcript
09:29pm, Thursday, 11'th Aug 2022
Start Time: 16:30 January 1, 0000 5:18 PM ET Lineage Cell Therapeutics, Inc. (NYSE:LCTX ) Q2 2022 Earnings Conference Call August 11, 2022, 16:30 PM ET Company Participants Brian Culley - CEO and Inte
A Quick Look At Lineage Cell Therapeutics And Its Product Development Efforts
12:08am, Wednesday, 20'th Jul 2022
Lineage Cell Therapeutics uses embryonic stem cells to develop cellular based drug therapies. The company's primary drug candidates are for the treatment of cancer, macular degeneration, and spinal co
Lineage Cell Therapeutics, Inc. (LCTX) CEO Brian Culley on Q1 2022 Results - Earning Calls Transcript
09:52pm, Thursday, 12'th May 2022
Lineage Cell Therapeutics, Inc. (NYSE:LCTX ) Q1 2022 Earnings Conference Call May 12, 2022 4:30 PM ET Company Participants Brian Culley – Chief Executive Officer Gary Hogge – Senior Vice President
Lineage Cell (LCTX) Reports Q1 Loss, Misses Revenue Estimates
07:34pm, Thursday, 12'th May 2022
Lineage Cell (LCTX) delivered earnings and revenue surprises of -500% and 56.62%, respectively, for the quarter ended March 2022. Do the numbers hold clues to what lies ahead for the stock?
Insiders Buy Over $1.3M Of 4 Penny Stocks
11:34am, Monday, 28'th Mar 2022
The Dow Jones tumbled more than 150 points on Monday. Investors, meanwhile, focused on some notable insider trades.
Lineage Cell Therapeutics, Inc. (LCTX) CEO Brian Culley on Q4 2021 Results - Earnings Call Transcript
09:11pm, Thursday, 10'th Mar 2022
Lineage Cell Therapeutics, Inc. (LCTX) CEO Brian Culley on Q4 2021 Results - Earnings Call Transcript
Lineage Cell (LCTX) Reports Q4 Loss
07:33pm, Thursday, 10'th Mar 2022
Lineage Cell (LCTX) delivered earnings and revenue surprises of -25% and 0%, respectively, for the quarter ended December 2021. Do the numbers hold clues to what lies ahead for the stock?
Why Lineage Cell Therapeutics Zoomed Higher Today
06:03pm, Monday, 20'th Dec 2021
The biotech stands to reap hundreds of millions of dollars from a new collaboration with a top pharmaceutical player.
Hot Penny Stocks To Buy For Under $5 Right Now
02:39pm, Monday, 20'th Dec 2021
Making a list of the best penny stocks to buy now? These 4 have turned heads in the stock market today.
Lineage, Genentech Ink Cell Therapy Licensing Pact For Ocular Diseases
09:01am, Monday, 20'th Dec 2021
Lineage Cell Therapeutics Inc (NYSE: LCTX) has entered into an exclusive worldwide collaboration and license agreement with Roche Holdings AG's (OTC: RHHBY) Genentech to develop and commercialize r
Lineage Cell Therapeutics (LCTX) Stock: Why The Price Jumped Today
03:21pm, Tuesday, 30'th Nov 2021
The stock price of Lineage Cell Therapeutics Inc (NYSEAMERICAN: LCTX) increased by 13% during intraday trading today. This is why it happened.
Lineage Cell Therapeutics, Inc. (LCTX) CEO Brian Culley on Q3 2021 Results - Earnings Call Transcript
08:20pm, Wednesday, 10'th Nov 2021
Lineage Cell Therapeutics, Inc. (LCTX) CEO Brian Culley on Q3 2021 Results - Earnings Call Transcript
Lineage Cell (LCTX) Reports Q3 Loss, Tops Revenue Estimates
07:50pm, Wednesday, 10'th Nov 2021
Lineage Cell (LCTX) delivered earnings and revenue surprises of 0.00% and 305.36%, respectively, for the quarter ended September 2021. Do the numbers hold clues to what lies ahead for the stock?
CARLSBAD, Calif.--(BUSINESS WIRE)---- $LCTX #LineageCellTherapeutics--Lineage Cell Therapeutics, Inc. (NYSE American and TASE: LCTX), a clinical-stage biotechnology company developing allogeneic cell
Lineage Cell Therapeutics' (LCTX) CEO Brian Culley on Q2 2021 Results - Earnings Call Transcript
08:42pm, Thursday, 12'th Aug 2021
Lineage Cell Therapeutics' (LCTX) CEO Brian Culley on Q2 2021 Results - Earnings Call Transcript
